In A20 tumor-bearing mice, combined treatment with anti-NKG2A and anti-PD-L1 mAbs rescued 75% of the mice from death compared to 40% in the anti-PD-L1 alone group (221). This evidence concerns the gene KLRC1 and neoplasm.